SCHEMBL5564787

SCHEMBL5564787

Cc1ccc(Cl)cc1Nc1ncnc2cc(F)ccc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.53
KMT2A Q03164 1/20 0.53
KDR P35968 7/20 0.51
FLT1 P17948 5/20 0.51
FGFR1 P11362 4/20 0.51
FLT4 P35916 2/20 0.51
EPHB2 P29323 1/20 0.51
SRC P12931 2/20 0.47
PPARG P37231 1/20 0.47
RXFP1 Q9HBX9 1/20 0.47
NR2E3 Q9Y5X4 1/20 0.47
NCOR2 Q9Y618 1/20 0.47
RET P07949 1/20 0.46
KIF5B P33176 1/20 0.46
MKNK1 Q9BUB5 3/20 0.46
IGF1R P08069 1/20 0.45
EPHB4 P54760 1/20 0.45
TEK Q02763 1/20 0.45
AURKB Q96GD4 1/20 0.45
LMNA P02545 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5568040 0.83 EGFR (0.60) MEN1KMT2AKDRFLT1FGFR1
SCHEMBL11082678 0.80 RXFP1 (0.63) KDRFLT1FGFR1FLT4EPHB2
SCHEMBL9017030 0.80 SRC (0.55) KDRFLT1FGFR1FLT4EPHB2
Hydrochloric Acid SCHEMBL11085544 0.79 RXFP1 (0.62) MEN1KMT2AKDRFLT1FGFR1
SCHEMBL5569117 0.79 HTT (0.61) MEN1KMT2AKDRFLT1FGFR1
Hydrochloric Acid SCHEMBL9017039 0.79 SRC (0.54) KDRFLT1FGFR1FLT4EPHB2
SCHEMBL28938261 0.77 MEN1 (0.53) MEN1KMT2AKDRFLT1FGFR1
SCHEMBL5569454 0.76 EGFR (0.74) MEN1KMT2ASRCMKNK1LMNA
SCHEMBL5568844 0.74 KDR (0.64) KDRFLT1FGFR1SRCIGF1R
SCHEMBL5569119 0.74 TP53 (0.50) KDRSRCPPARGRXFP1NR2E3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070123537-A1 Quinazoline derivatives for the treatment of herpesviral infections GPC BIOTECH AG (DE) 2007-05-31 US claimed
EP-1673346-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS GPC Biotech AG (DE) 2006-06-28 EP claimed
WO-2005040125-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS GPC BIOTECH AG (DE) 2005-05-06 WO claimed
US-20070123537-A1 Quinazoline derivatives for the treatment of herpesviral infections GPC BIOTECH AG (DE) 2007-05-31 US disclosed
EP-1673346-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS GPC Biotech AG (DE) 2006-06-28 EP disclosed
WO-2005040125-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS GPC BIOTECH AG (DE) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070123537-A1 Quinazoline derivatives for the treatment of herpesviral infections IRF3, PML, TPMT MEN1 1784/4885KMT2A 1230/4885KDR 2712/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.